High materiality7/10
Oppenheimer Reiterates Outperform Rating on Biogen (BIIB)
Why it may matterVerify against the original reporting
buy
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Oppenheimer reiterates Outperform on BIIB; target 300; price 209.23.
- Oppenheimer BIIB Target 300; price 209.23
Key facts
- 01
Target: $300
- 02
Posted price: $209.23
- 03
Analyst firm: Oppenheimer
- 04
Analyst: Jay Olson
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.